MedTrace Logo

Study Evaluating Safety and Efficacy of INCB050465 Combined With Bendamustine and Obinutuzumab in Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

NCT03039114 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 26

Last updated 2025-08-21

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and efficacy of parsaclisib when combined with bendamustine and obinutuzumab in subjects with relapsed or refractory follicular lymphoma (FL).

Conditions

Interventions

DRUG

Parsaclisib

Parsaclisib at the protocol-defined starting dose administered once daily for 8 weeks followed by once weekly.

DRUG

Hexal

Bendamustine 90 mg/m\^2 administered intravenously at protocol-defined timepoints.

DRUG

Gazyvaro

Obinutuzumab 1000 mg by intravenous infusion at protocol-defined timepoints.

Sponsors & Collaborators

Principal Investigators

  • Fitzroy Dawkins, MD · Incyte Corporation

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-02-15
Primary Completion
2021-03-30
Completion
2021-03-30
FDA Drug
Yes

Countries

  • United States
  • Czechia
  • Denmark
  • Hungary
  • Italy
  • Spain

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03039114 on ClinicalTrials.gov